Arpida sells iclaprim to Acino and prepares for Evolva merger
This article was originally published in Scrip
Executive Summary
Arpida has sold its diaminopyrimidine antibiotic iclaprim to fellow Swiss firm Acino for CHF2.1 million ($2.05 million). Development of the drug, which Arpida licensed from Roche and was developing under the name Mersarex, ran aground after the EU's CHMP issued a negative opinion last month (scripnews.com, October 26th, 2009). In the US, the FDA issued a complete response letter requiring further clinical trials which the company deemed to be too costly. An earlier FDA panel had recommended against its approval saying that Arpida had failed to show non-inferiority to linezolid (Pfizer's Zyvox).
You may also be interested in...
Gaming Whiz Brings AI Smarts To Drug Discovery
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
The Top 10 Best-Selling Drugs of 2019
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Interview: Why Biotech Companies Should Be Confident About Deals Despite Coronavirus
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
Need a specific report? 1000+ reports available
Buy Reports